SG&A at other companies
Other financials
Where this comes from
Reported directly by Axsome Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.
The official record: Axsome Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Axsome Therapeutics's sg&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Axsome Therapeutics's SG&A?
- Axsome Therapeutics (AXSM) reported SG&A of $185M in Q1 2026.
- How has Axsome Therapeutics's SG&A changed year-over-year?
- Axsome Therapeutics's SG&A increased by 53.2% year-over-year, from $120.79M to $185M.
- What is the long-term trend for Axsome Therapeutics's SG&A?
- Over 4 years (2021 to 2025), Axsome Therapeutics's SG&A has grown at a 71.1% compound annual growth rate (CAGR), from $66.65M to $570.6M.
- What does SG&A mean?
- Operating costs related to marketing, sales, and general corporate management.
- How do you interpret SG&A?
- An increase often signals commercial expansion or scaling, while excessive growth relative to revenue may indicate operational inefficiency.
- How does SG&A compare across companies?
- Commonly benchmarked as a percentage of revenue to assess commercial efficiency relative to peers.